

[receptor] on the CD28 positive T cells with the soluble B7 protein and thereby inhibiting T cell proliferation. 503 LI

K
3
--80.

(Amended) The method of claim 79, wherein the soluble B7 fusion protein has an amino acid sequence containing amino acid residues from about position 1 to about position 215 of the amino acid sequence corresponding to the extracellular domain of B7 [antigen] which recognizes and binds the CD28 positive T cells.

--81.

(Amended) The method of claim 79, wherein the soluble B7 fusion protein comprises a fusion polypeptide having a first amino acid sequence corresponding to the extracellular domain of B7 [antigen] which recognizes and binds [the] CD28 [antigen] and a second amino acid sequence corresponding to a moiety that alters the solubility, affinity, and/or valency of the soluble B7 fusion protein for binding to [the] CD28 [receptor].

K²
7
--84.
6

(Amended) The method of claim 79, wherein the soluble B7 fusion protein comprises a fusion polypeptide having a first amino acid sequence containing amino acid residues from about position 1 to about position 215 of the amino acid sequence corresponding to the extracellular domain of the soluble B7 fusion protein which recognizes and binds [the] CD28 [antigen] and a second amino acid sequence corresponding to the hinge, CH2, and CH3 regions of human immunoglobulin Cγ1.

--85.

(Amended) A method for inhibiting [preventing] the binding of [the] CD28 positive T cells [receptor] to [a] B7 positive B cells [antigen] comprising contacting the CD28 positive T cells with a soluble B7 fusion protein which recognizes and

binds [the] CD28 [receptor] on the CD28 positive T cells thereby preventing binding of CD28 [the receptor] to the B7 positive B cells [antigen].

8
--86.

(Amended) The method of claim ⁷85, wherein the soluble B7 fusion protein is a B7Ig fusion protein comprising an amino acid sequence containing amino acid residues from about position 1 to about position 215 of the amino acid sequence corresponding to the extracellular domain of [the] B7 [antigen] which recognizes and binds CD28.--

9
--87.

(Amended) The method of claim ⁸86, wherein the fusion protein is B7Ig fusion protein [corresponding to] having the amino acid sequence encoded by DNA contained in the plasmid having ATCC No. 68627.

K2
--88.

(Amended) A method of inhibiting CD28 positive T cell [activation] responses comprising reacting B7 positive B cells with a soluble CD28 fusion protein so as to bind the B7 positive B cells with the soluble CD28 fusion protein thereby inhibiting T cell [activation] responses. SUB 2

11
--89.

(Amended) The method of claim ¹⁰88, wherein the soluble CD28 fusion protein comprises a polypeptide having an amino acid sequence containing amino acid residues from about position 1 to about position 134 of the amino acid sequence corresponding to the extracellular domain of CD28 [receptor].

12
--90.

(Amended) The method of claim ¹¹89, wherein the soluble CD28 fusion protein has a first amino acid sequence corresponding to the extracellular domain of CD28 [receptor] and a second amino acid sequence corresponding to a moiety that alters

K2 the solubility, affinity, and/or valency of the CD28 [receptor] for binding to B7 positive B cells [antigen].

--93.
15

(Amended) The method of claim ¹⁰88, wherein the soluble CD28 fusion protein comprises a polypeptide having a first amino acid sequence containing amino acid residues from about position 1 to about position 134 of the amino acid sequence corresponding to the extracellular domain of CD28 [receptor] and a second amino acid sequence corresponding to the hinge, CH2, and CH3 regions of human immunoglobulin Cγ1.

K3
--94.
16

(Amended) The method of claim ¹⁵93, wherein the fusion protein is CD28Ig fusion protein [corresponding to] having the amino acid sequence encoded by DNA contained in the plasmid having ATCC No. 68628.

--95.

(Amended) A method for inhibiting [preventing] the binding of the B7 positive B cells [receptor] to a CD28 positive T cells [antigen] comprising contacting B7 positive cells with a soluble CD28 fusion protein which recognizes and binds [the] B7 [receptor] on the B7 positive cells thereby preventing binding of the B7 positive B cells [receptor] to the CD28 positive T cells [antigen].

--96.

(Amended) The method of claim 95, wherein the soluble CD28 fusion protein is a CD28Ig fusion protein comprising an amino acid sequence containing amino acid residues from about position 1 to about position 134 of the amino acid sequence corresponding to the extracellular domain of [the] CD28 [receptor] which recognizes and binds [the] B7 [antigen].